Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Florian MärklMohamed-Reda BenmebarekJulius KeylBruno L CadilhaMartina GeigerClara KarchesHannah ObeckMelanie SchwerdtfegerStefanos MichaelidesDaria BriukhovetskaSophia StockJakob JobstPhilipp Jie MüllerLina MajedMatthias SeifertAnna-Kristina KlüverTheo LorenziniRuth GrünmeierMoritz ThomasAdrian GottschlichRichard KlausCarsten MarrMichael von Bergwelt-BaildonSimon RothenfusserMitchell P LevesqueMarkus Vincent HepptStefan EndresChristiane NeumannSebastian KoboldPublished in: Journal for immunotherapy of cancer (2023)
The SAR T cell-BiAb approach delivers specific and conditional T cell activation as well as targeted tumor cell lysis in melanoma models. Modularity is a key feature for targeting melanoma and is fundamental towards personalized immunotherapies encompassing cancer heterogeneity. Because antigen expression may vary in primary melanoma tissues, we propose that a dual approach targeting two tumor-associated antigens, either simultaneously or sequentially, could avoid issues of antigen heterogeneity and deliver therapeutic benefit to patients.
Keyphrases
- single cell
- skin cancer
- cancer therapy
- end stage renal disease
- ejection fraction
- basal cell carcinoma
- poor prognosis
- machine learning
- gene expression
- peritoneal dialysis
- deep learning
- newly diagnosed
- squamous cell carcinoma
- drug delivery
- chronic kidney disease
- papillary thyroid
- dendritic cells
- binding protein
- stem cells
- patient reported outcomes
- long non coding rna